2/23/2022 8:19:31 AM
Clovis Oncology Q4 Net Loss $64.4 Mln Or $0.50/shr Vs. Loss $99.0 Mln Or $1.02/shr Prior Year
1/10/2022 8:10:06 AM
Clovis Oncology : $35.5 Mln - $36.1 Mln In Estimated Rubraca Global Product Revenues For Q4
11/3/2021 8:17:13 AM
Clovis Oncology Q3 Net Loss $67.4 Mln Vs Net Loss $78.7 Mln Last Year
10/19/2021 8:11:53 AM
Clovis Oncology And ITM Announce Lutetium-177 Supply Agreement
6/23/2021 7:04:18 AM
Clovis Oncology Says Phase 1/2 LuMIERE Study Of FAP-2286 Now Open For Enrollment
2/27/2018 8:59:50 AM
RBC Capital Markets Is Lowering Clovis Oncology, Inc. (CLVS) FY18 Rev. Estimate To 122.8 M From 131.5 M
2/27/2018 8:59:37 AM
RBC Capital Markets Is Cutting Clovis Oncology, Inc. (CLVS) Q1 18 Rev. Estimate To 18.1 M From 19.6 M
2/27/2018 8:59:19 AM
RBC Capital Markets Is Increasing Clovis Oncology, Inc. (CLVS) FY19 Estimate To -1.64 From -2.02
2/27/2018 8:59:05 AM
RBC Capital Markets Is Raising Clovis Oncology, Inc. (CLVS) FY18 Estimate To -5.34 From -5.65
2/27/2018 8:58:51 AM
RBC Capital Markets Is Increasing Clovis Oncology, Inc. (CLVS) Q1 18 Estimate To -1.39 From -1.46
11/2/2017 12:04:41 PM
RBC Capital Markets Is Cutting Clovis Oncology, Inc. (CLVS) 4Q17 Rev. Estimate To 20.9 M From 26.1 M
11/2/2017 12:04:19 PM
RBC Capital Markets Is Raising Clovis Oncology, Inc. (CLVS) 2019 Estimate To -1.34 From -1.59
11/2/2017 12:03:58 PM
RBC Capital Markets Is Increasing Clovis Oncology, Inc. (CLVS) 2018 Estimate To -3.84 From -4.19
11/2/2017 12:03:35 PM
RBC Capital Markets Is Raising Clovis Oncology, Inc. (CLVS) 2017 Estimate To -7.65 From -7.79
11/2/2017 12:03:20 PM
RBC Capital Markets Is Lowering Clovis Oncology, Inc. (CLVS) 2017 Rev. Estimate To 59.4 M From 68.6 M